Skin diseases, responding to treatment with corticosteroids with associated or secondary bacterial and / or fungal infection: eczema (including atopic, pediatric and pediatric), nodular itch, psoriasis (excluding generalized changes), lichen planus, lichen simple, seborrheic dermatitis , contact type allergies, anastomosis and sexual organs, large reactions after insect bites.
Composition:
1 g Ointment or cream contains 1.22 mg of micronised betamethasone valerate and 30 mg of clioquinol.
Action:
A preparation for topical application. A topical corticosteroid - Betamethasone valerate - has anti-inflammatory properties. Clioquinol is a chemotherapy agent that exerts antibacterial and antifungal activity. Topically applied corticosteroids may be absorbed by healthy, intact skin. Inflammation and / or other skin disease processes increase their penetration through the skin. Occlusive dressings significantly increase the transcutaneous absorption of topically applied corticosteroids. When absorbed into the body through the skin, topically applied corticosteroids are metabolized similar to systemic corticosteroids.
Contraindications:
Hypersensitivity to betamethasone valerate, clioquinol or other components of the preparation. Rosacea. Common acne. Inflammation of the skin around the mouth. Pruritus of the anus and genital area. Skin infection caused by viruses (eg herpes simplex, chicken pox), bacteria or fungi. In children under 1 year of age in skin diseases with inflammatory skin changes and diaper rash including.
Precautions:
Long-term use of the medicinal product should be avoided, especially in children, due to the possibility of suppression of the hypothalamic-pituitary-adrenal axis and symptoms of Cushing's syndrome, even without the use of an occlusive dressing. The use of corticosteroids on the facial skin may lead, more often than when applied to the skin of other parts of the body, to skin atrophy - this should be taken into account, especially in the treatment of psoriasis and increased eczema. Avoid use on the eyelids, because getting the medicinal product into the conjunctival sac can lead to glaucoma. The spread of infection is an indication to stop the use of topical corticosteroids. Topical use of corticosteroids in psoriasis may be disadvantageous for the following reasons: the risk of tolerance to the preparation, the risk of exacerbation of changes as a result of the so-called "rebound effect" after discontinuation of the preparation, risk of development of generalized pustular psoriasis, risk of local or systemic side effects of corticosteroids resulting from excessive absorption of the medicinal product through damaged skin. There is a risk of neurotoxic effects of topically applied clioquinol, especially when the preparation is used for a long time or under an occlusive dressing. Due to the content of cetostearyl alcohol, the cream may cause a local skin reaction (eg contact dermatitis), due to the content of chlorocresol may cause hypersensitivity reactions.
Pregnancy and lactation:
The use of preparations during pregnancy and breastfeeding is not recommended, especially at high doses and on large areas of the skin. The local use of corticosteroids in pregnant animals caused fetal malformations.
Side effects:
Common: local skin burning and pruritus. Very rare: hypersensitivity (the drug should be immediately discontinued), symptoms of hypercortisolism - Cushing's syndrome, dilation of superficial blood vessels, thinning of the skin, stretch marks, hyperpigmentation, exacerbation of symptoms, allergic contact dermatitis, pustular psoriasis.
Dosage:
The cream is intended for use on moist, oozing skin lesions; ointment for dry, lichen-like, flaky skin lesions. A small amount of cream or ointment should be covered by affected lesions on the skin 2 or 3 times a day until improvement occurs.In order to maintain the therapeutic effect, it can be used once a day or less frequently. In treatment-resistant conditions (eg psoriatic lesions on the elbows and knees) the effectiveness of the preparations can be increased by using an occlusive dressing (eg polyethylene film) only overnight. The improvement can be sustained by regular use of the drug without an occlusive dressing. In the absence of clinical improvement, the medicinal product should not be used for more than 7 days. If the product is applied to the face, treatment should be limited to 5 days and the occlusive dressing should not be used. In children, the preparations can be used for up to 5 days, do not use occlusive dressings.
(C)
